{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:28:29Z","timestamp":1770935309705,"version":"3.50.1"},"reference-count":179,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1517\/13543784.10.7.1291","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T15:34:27Z","timestamp":1115220867000},"page":"1291-1308","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension"],"prefix":"10.1517","volume":"10","author":[{"given":"Ronald G","family":"Tilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommy A","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard AF","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"e_1_2_1_5_1","unstructured":"WEIR EK ARCHER SL RUBIN LJ: Pulmonary hypertension. In: Cardiovascular Medicine. Willerson JT and Cohn JN (Eds.) Churchill Livingstone New York USA (1995):1495\u20131523."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960200804"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/79226"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-199610000-00016"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12019-000-0008-7"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.4065\/75.6.625"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460080084038"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00004"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02889609"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.22.2781"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02111-4"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.59.1.89"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507273330403"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282402"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09020356"},{"key":"e_1_2_1_21_1","first-page":"252","article-title":"Calcium channel blockers for thetreatment of primary pulmonary hypertension","volume":"29","author":"RICH S","year":"1995","unstructured":"RICH S: Calcium channel blockers for thetreatment of primary pulmonary hypertension. Eur. Respir: Rev. (1995) 29:252\u2013254.","journal-title":"Eur. Respir: Rev."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440270057005"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.6.1479"},{"key":"e_1_2_1_24_1","first-page":"296","volume":"334","author":"BARST RJ","year":"1998","unstructured":"BARST RJ, RUBIN LJ, LONG W etal.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl. I Med. (1998) 334:296\u2013301.","journal-title":"LONG W etal.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl. I Med."},{"key":"e_1_2_1_25_1","first-page":"273","volume":"338","author":"MCLAUGHLIN VV","year":"1998","unstructured":"MCLAUGHLIN VV, GENTHNER DE, PANELLA MM etal.: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Eng] Med. (1998) 338:273\u2013277.","journal-title":"PANELLA MM etal.: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Eng] Med."},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00187-3"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.20.2388"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422503"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1996.80.1.252"},{"key":"e_1_2_1_30_1","first-page":"700","volume":"15","author":"GIRARD C","year":"1996","unstructured":"GIRARD C, FARGNOLI JM, GODIN-RIBUOT D eta].: Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension. j Heart Lung Trans. (1996) 15:700\u2013708.","journal-title":"GODIN-RIBUOT D eta].: Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension. j Heart Lung Trans."},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1601"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199503000-00003"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199907000-00003"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702273360901"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.101.3.325"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199109001-00988"},{"key":"e_1_2_1_37_1","doi-asserted-by":"crossref","unstructured":"KATAYAMA Y HIGENBOTTAM TW CREMONA G etal.: Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas. Circulation (1998) 98(22):2429\u20132432.","DOI":"10.1161\/01.CIR.98.22.2429"},{"key":"e_1_2_1_38_1","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1152\/jappl.1993.74.4.1704","article-title":"Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed","volume":"74","author":"MCMAHON TJ","year":"1993","unstructured":"MCMAHON TJ, IGNARRO LJ, KADOWITZ PJ: Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. j App. Physiol (1993) 74:1704\u20131711.","journal-title":"j App. Physiol"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199802000-00020"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200006000-00030"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200003000-00014"},{"key":"e_1_2_1_42_1","unstructured":"\u2022A good review of phosphodiesterase inhibitors as potential drugs."},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011023431814"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199907000-00041"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.5.9901102"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199904000-00015"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200006000-00044"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/332411a0"},{"key":"e_1_2_1_49_1","unstructured":"\u2022\u2022First report of a potent vasoconstrictingpeptide."},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6964"},{"key":"e_1_2_1_51_1","unstructured":"\u2022\u2022First identification of endothelin."},{"key":"e_1_2_1_52_1","doi-asserted-by":"crossref","unstructured":"INOUE A YANAGISAWA M KIMURA S etal.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Nati Acad. Li. USA (1989) 86(8):2863\u20132867.","DOI":"10.1073\/pnas.86.8.2863"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)91461-K"},{"key":"e_1_2_1_54_1","doi-asserted-by":"crossref","unstructured":"EHRENREICH H ANDERSON RW FOX CH etal.: Endothelins peptides with potent vasoactive properties are produced by human macrophages. I Exp. Med. (1990) 172(6):1741\u20131748.","DOI":"10.1084\/jem.172.6.1741"},{"issue":"9","key":"e_1_2_1_55_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1091\/mbc.1.9.649","article-title":"SCOTT-BURDEN T, POWELL J, DOHI Y, BUHLER FR: Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function","volume":"1","author":"HAHN AW","year":"1990","unstructured":"HAHN AW, RESINK TJ, SCOTT-BURDEN T, POWELL J, DOHI Y, BUHLER FR: Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Reg. (1990) 1(9):649\u2013659.","journal-title":"Cell Reg."},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.19.2434"},{"key":"e_1_2_1_57_1","unstructured":"\u2022\u2022A comprehensive review of the role ofendothelin in cardiovascular disease."},{"issue":"4","key":"e_1_2_1_58_1","first-page":"261","article-title":"Molecular pharmacology and pathophysiological significance of endothelin","volume":"72","author":"GOTO K","year":"1996","unstructured":"GOTO K, HAMA H, KASUYA Y: Molecular pharmacology and pathophysiological significance of endothelin. fpri. j Pharmacol. (1996) 72(4):261\u2013290.","journal-title":"fpri. j Pharmacol."},{"key":"e_1_2_1_59_1","doi-asserted-by":"crossref","unstructured":"CHEN Y-F OPARIL S: Endothelin and pulmonary hypertension. j Cardiovasc. Pharmacol. (2000) 35\\(Suppl. 2):549\u2013553.","DOI":"10.1097\/00005344-200000002-00012"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.61.1.391"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(97)01144-9"},{"issue":"18","key":"e_1_2_1_62_1","first-page":"10446","article-title":"Functional analysis of the endothelin-1 gene promotor","volume":"265","author":"LEE ME","year":"1990","unstructured":"LEE ME, BLOCH KD, CLIFFORD JA, QUERTERMOUS T: Functional analysis of the endothelin-1 gene promotor. Evidence for an endothelial cell-specific cis-acting sequence. j Biol. Chem. (1990) 265(18):10446\u201310450.","journal-title":"Evidence for an endothelial cell-specific cis-acting sequence. j Biol. Chem."},{"issue":"25","key":"e_1_2_1_63_1","first-page":"14954","article-title":"The human preproendothelin-1 gene","volume":"264","author":"INOUE A","year":"1989","unstructured":"INOUE A, YANAGISAWA M, TAKUWA Y, MITSUI Y, KOBAYASHI M, MASAKI T: The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. j Biol. Chem. (1989) 264(25):14954\u201314959.","journal-title":"Complete nucleotide sequence and regulation of expression. j Biol. Chem."},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb12035.x"},{"issue":"2","key":"e_1_2_1_65_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0021-9258(18)48426-8","article-title":"Human transcription factor GATA-2: evidence for regulation of preproendothelin-1 gene expression in endothelial cells","volume":"267","author":"DORFMAN DM","year":"1992","unstructured":"DORFMAN DM, WILSON DB, BRUNS GA, ORKIN SH: Human transcription factor GATA-2: evidence for regulation of preproendothelin-1 gene expression in endothelial cells. j Biol. Chem. (1992) 267(2):1279\u20131285.","journal-title":"j Biol. Chem."},{"key":"e_1_2_1_66_1","doi-asserted-by":"crossref","unstructured":"DENAULT JB CLAING A D'ORLEANS-JUSTE P et al.: Processing of proendothelin-1 by human furin convertase. FEBS Lett. (1995) 362(3):276\u2013280.","DOI":"10.1016\/0014-5793(95)00249-9"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90425-1"},{"key":"e_1_2_1_68_1","unstructured":"\u2022Contributed significantly to our understanding of endothelin processing and activation."},{"key":"e_1_2_1_69_1","doi-asserted-by":"crossref","unstructured":"SCHWEIZER A VALDENAIRE 0 NELBOCK P etal.: Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localization. Biochem. J (1997) 328(6):871\u2013877.","DOI":"10.1042\/bj3280871"},{"key":"e_1_2_1_70_1","doi-asserted-by":"crossref","unstructured":"VALDENAIRE 0 LEPAILLEUR-ENOUF D EGIDY G et al.: A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular coloning and characterization. Eur. j Biochem. (1999) 264(2):341\u2013349.","DOI":"10.1046\/j.1432-1327.1999.00602.x"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.25.15262"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90252-E"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3270023"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701564"},{"key":"e_1_2_1_75_1","doi-asserted-by":"crossref","unstructured":"FUKUCHI M GIAID A: Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. j Cardiovasc. Pharmacol. (1998) 31\\(Suppl. 1):S421\u2013S423.","DOI":"10.1097\/00005344-199800001-00120"},{"issue":"15","key":"e_1_2_1_76_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1242\/dev.125.5.825","article-title":"Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene","volume":"125","author":"YANAGISAWA H","year":"1998","unstructured":"YANAGISAWA H, YANAGISAWA M, KAPUR RP et al.: Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development (1998) 125(15):825\u2013836.","journal-title":"Development"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1462"},{"key":"e_1_2_1_78_1","doi-asserted-by":"crossref","first-page":"C389\u2013C396","DOI":"10.1152\/ajpcell.1992.263.2.C389","article-title":"Physiological fluidshear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium","volume":"263","author":"MALEK A","year":"1992","unstructured":"MALEK A, IZUMO S: Physiological fluidshear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am. j Physiol. (1992) 263:C389\u2013C396.","journal-title":"Am. j Physiol."},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI854"},{"issue":"6","key":"e_1_2_1_80_1","first-page":"H2105\u2013H2112","article-title":"Prolonged exercise causes an increase in endothelin-1 production in the heart in rats","volume":"275","author":"MAEDA S","year":"1998","unstructured":"MAEDA S, MIYAUCHI T, SAKAI S et al.:Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. Am. J. Physiol. (1998) 275(6):H2105\u2013H2112.","journal-title":"Am. J. Physiol."},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)91989-6"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.70.6.1191"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(90)80276-O"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(96)05836-4"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.1.329"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/0008-6363(95)00168-9"},{"key":"e_1_2_1_87_1","unstructured":"BARTON M LATTMANN T SHAW S et al.: Aging a cardiovascular risk factor markedly increases expression of endothelin-1 in vivo independent of blood pressure and endothelin-1 clearance. j Am. Coll. Cardiol. (1999) 33:225 (Abstract)."},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114477"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.19.6.753"},{"key":"e_1_2_1_90_1","doi-asserted-by":"crossref","unstructured":"CORDER R CARRIER M KHAN N KLEMM P VANE JR: Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. j Cardiovasc. Pharmacol. (1995) 26\\(Suppl. 3):S56\u2013S58.","DOI":"10.1097\/00005344-199526003-00018"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009749609069994"},{"key":"e_1_2_1_92_1","doi-asserted-by":"crossref","unstructured":"ARAI H HORT S ARAMORI I OHKUBO H NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348(6303)730\u2013732.","DOI":"10.1038\/348730a0"},{"key":"e_1_2_1_93_1","unstructured":"\u2022First description of the endothelin A receptor."},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.8.3185"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/348732a0"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)90158-4"},{"key":"e_1_2_1_97_1","unstructured":"\u2022First description of the human endothelin B receptor."},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(92)90109-9"},{"key":"e_1_2_1_99_1","doi-asserted-by":"crossref","unstructured":"HIRATA Y EMORI T EGUCHI S etal.: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. j Clirr. Invest. (1993) 91(4):1367\u20131373.","DOI":"10.1172\/JCI116338"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.5.1198"},{"key":"e_1_2_1_101_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.3.234"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1527"},{"key":"e_1_2_1_103_1","doi-asserted-by":"crossref","unstructured":"HAYNES WG STRACHAN FE GRAY GA WEBB DJ: Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. Cardiovasc. Pharmacol. (1995) 26\\(Suppl. 3):S40\u2013S43.","DOI":"10.1097\/00005344-199506263-00013"},{"key":"e_1_2_1_104_1","doi-asserted-by":"crossref","unstructured":"MCCULLOCH KM MACLEAN MR: Endothelin B receptor-mediated contracton of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. j Cardiovasc. Pharmacol. (1995) 26\\(Suppl. 3):S169\u2013S176.","DOI":"10.1097\/00005344-199506263-00052"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14767.x"},{"issue":"10","key":"e_1_2_1_106_1","first-page":"2139","article-title":"Cyclic pentapeptide endothelin antagonist with high ETA selectivity","volume":"35","author":"ISHIKAWA K","year":"1992","unstructured":"ISHIKAWA K, FUKAMI T, NAGASE T et al.: Cyclic pentapeptide endothelin antagonist with high ETA selectivity. Potency- and solubility-enhancing modifications. j Med. Chem. (1992) 35(10:2139\u20132142.","journal-title":"Potency- and solubility-enhancing modifications. j Med. Chem."},{"issue":"2","key":"e_1_2_1_107_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0022-3565(25)22432-6","article-title":"A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats","volume":"270","author":"IKEDA S","year":"1994","unstructured":"IKEDA S, AWANE Y, KUSUMOTO K, WAKIMASU M, WATANABE T, FUJINO M: A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J. Pharmacol. Exp. Ther. (1994) 270(2):728\u2013733.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.10.11.1653"},{"key":"e_1_2_1_109_1","unstructured":"\u2022Excellent report on current status of the chemistry effort to develop new endothelin receptor antagonists."},{"issue":"4","key":"e_1_2_1_110_1","first-page":"339","article-title":"R: Endothelin receptor antagonists: a clinical study update","volume":"2","author":"WU-WONG JR","year":"2000","unstructured":"WU-WONG JR, PADLEY R: Endothelin receptor antagonists: a clinical study update. Cun: Opin. in Cardiovasc. Pulmon. & Renal Invest. Drugs (2000) 2(4):339\u2013344.","journal-title":"Cun: Opin. in Cardiovasc. Pulmon. & Renal Invest. Drugs"},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1395"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.8.752"},{"key":"e_1_2_1_113_1","first-page":"1147","article-title":"Effect of novel mixed ETA\/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries","volume":"11","author":"MACLEAN MR","year":"1998","unstructured":"MACLEAN MR, DOCHERTY CC, MCCULLOCH KM, MORECROFT I: Effect of novel mixed ETA\/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries. Pulliam Pharmacol. Therm. (1998) 11:1147\u2013149.","journal-title":"Pulliam Pharmacol. Therm."},{"key":"e_1_2_1_114_1","unstructured":"NOVEL TREATMENTS FOR PULMONARY HYPERTENSION: IBC Conference: New Understanding for Therapeutic Development San Diego California USA IDdb Meeting Report (1998)."},{"key":"e_1_2_1_115_1","unstructured":"CHANNICK RN RUBIN LJ SIMONNEAU G et al.: Bosentan a dual endothelin receptor antagonist improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: results of a double blind randomized placebo-controlled trial. Circulation (2000) 102(18):II\u2013100 (Abstract)."},{"key":"e_1_2_1_116_1","unstructured":"\u2022One of the first Phase III clinical trial reports that endothelin receptor antagonism with bosentan is efficacious in the treatment of pulmonary hypertension."},{"key":"e_1_2_1_117_1","doi-asserted-by":"publisher","DOI":"10.1006\/pupt.2000.0237"},{"key":"e_1_2_1_118_1","unstructured":"BARST RJ RICH S HORN EM et al.: Efficacy and safety of chronic treatment with oral selective endothelin-A receptor blocker Sitaxsentan in pulmonary arterial hypertension (PAH). Circulation (2000) 102(18): 11\u2013427 (Abstract)."},{"key":"e_1_2_1_119_1","unstructured":"CALHOUN DA RENFROE K ALPER AB: Oral sitaxsentan an endothelin-A selective receptor antagonist reduces systemic blood pressure in patients with mild-to-moderate primary hypertension. Circulation (2000) 102(18):11\u2013417 (Abstract)."},{"key":"e_1_2_1_120_1","first-page":"2072","article-title":"The ETA receptor antagonist, TBC3711, reverses pulmonary hypertension in the neonatal piglet and restores the dilator response to NO","volume":"102","author":"PERREAULT T","year":"2000","unstructured":"PERREAULT T, BERKENBOSCH JW, BROCK T, BARIBEAU J: The ETA receptor antagonist, TBC3711, reverses pulmonary hypertension in the neonatal piglet and restores the dilator response to NO. Circulation (2000) 102:2072.","journal-title":"Circulation"},{"key":"e_1_2_1_121_1","doi-asserted-by":"crossref","unstructured":"KEISER JA SCHROEDER RL HALLAK H UPRICHARD ACG DOHERTY AM HALEEN SJ : Pharmacodynamics of PD 156707 a selective endothelin receptor-A (ET-A) antagonist in acute hypoxic pulmonary hypertension (PH). FASEB (1997) 11:A36 (Abstract). Ica PETROSSIAN E PARRY AJ REDDY VM et al.: Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow. J. Thor. Cardiovas. Surg.(1999) 117:314\u2013323.","DOI":"10.1016\/S0022-5223(99)70429-0"},{"key":"e_1_2_1_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199800001-00092"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.1.71"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00253.x"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00954-5"},{"key":"e_1_2_1_126_1","doi-asserted-by":"crossref","unstructured":"OHLSTEIN EH NAMBI P LAGO A: Nonpeptide endothelin receptor antagonists: VI. Pharmacological characterization of SB217242 a potent and highly bioavailable endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276(2):609\u2013615.","DOI":"10.1016\/S0022-3565(25)12314-8"},{"issue":"653","key":"e_1_2_1_127_1","first-page":"658","article-title":"apos;s Conference on Pulmonary Hypertension: New Understanding for Therapeutic Development","volume":"7","author":"BIALECKI RA","year":"1998","unstructured":"BIALECKI RA: IBC's Conference on Pulmonary Hypertension: New Understanding for Therapeutic Development. Expert Opiri. Investig. Drugs (1998) 7:653 658.","journal-title":"Expert Opiri. Investig. Drugs"},{"key":"e_1_2_1_128_1","first-page":"1561","article-title":"Effects of SB 217242, a non-selective endothelin (ET)-A and ET-B receptor antagonist, in healthy humans","volume":"7","author":"FREED MI","year":"1996","unstructured":"FREED MI, THOMPSON KA, WILSON DE, OHLSTEIN EH, DENNIS M, JORKASKY DK: Effects of SB 217242, a non-selective endothelin (ET)-A and ET-B receptor antagonist, in healthy humans. J. Am. So. Nephrol. (1996) 7:1561.","journal-title":"J. Am. So. Nephrol."},{"key":"e_1_2_1_129_1","unstructured":"NORMAN P: COPD: New Developments & Therapeutic Opportunities; National Heart & Lung Institute London UK. IDdb Meeting Report (1999)."},{"key":"e_1_2_1_130_1","unstructured":"THOMAS S: American Chemical Society 219th National Meeting (Part III) Division of Medicinal Chemistry Poster Session and General Papers San Francisco CA USA. IDdb Meeting Report (2000)."},{"key":"e_1_2_1_131_1","doi-asserted-by":"crossref","unstructured":"MURUGESAN N GU Z STEIN P et al.: Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazoly1 biphenylsulfonamides as a new class of potent highly selective ETA antagonists. J. Med. Chem. (2000) 43:3111\u20133117.","DOI":"10.1021\/jm000105c"},{"key":"e_1_2_1_132_1","doi-asserted-by":"crossref","unstructured":"COE JY COCEANI F HALEEN SJ WELCH KM: The ETA receptor antagonist PD180988 selectively reverses the pulmonary vasconstrictor response to hypoxia in the lamb. Circulation (2000) 102(18):2710 (Abstract).","DOI":"10.1097\/00005344-200036001-00096"},{"key":"e_1_2_1_133_1","unstructured":"TORRE-AMIONE G DURAND JB BOZKURT B: Results of a randomised placebo-controlled hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure. Circulation (1999) 100:3410 (Abstract)."},{"key":"e_1_2_1_134_1","doi-asserted-by":"crossref","unstructured":"LIU G HENRY KJ SZCZEPANKIEWICZ BG etal.: Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent 2-nonaryl highly selective ETA antagonist (A-216546). J. Med. Chem. (1998) 41(17):3261\u20133275.","DOI":"10.1021\/jm980217s"},{"key":"e_1_2_1_135_1","unstructured":"ADLER AL: Inhibition and reversal of acute ET-1-induced hypertension by A-147627 an orally active non-peptide ETA-selective receptor antagonist. FASEB J. (1996) 10:4009 (Abstract)."},{"key":"e_1_2_1_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(98)00169-2"},{"key":"e_1_2_1_137_1","first-page":"2871","article-title":"B: Neurohumoral and hemodynamic effects of the selective endothelin anatgonist LU 135252 in advanced heart failure","volume":"102","author":"BERGLER-KLEIN J","year":"2000","unstructured":"BERGLER-KLEIN J, PACHER R, BERGER R, BOJIC A, STANEK B: Neurohumoral and hemodynamic effects of the selective endothelin anatgonist LU 135252 in advanced heart failure. Circulation (2000) 102:2871.","journal-title":"Circulation"},{"key":"e_1_2_1_138_1","unstructured":"RUSCHITZKA FT PACHER R KRANKENHAUS A et al.: Chronic selective ETA receptor blockade in congestive heart failure: The heat trial (Heart failure ETA receptor blockade trial) Circulation (2000) 102(18):11\u2013593 (Abstract)."},{"key":"e_1_2_1_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00115-7"},{"key":"e_1_2_1_140_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118332"},{"key":"e_1_2_1_141_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2750"},{"key":"e_1_2_1_142_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.74.2.349"},{"key":"e_1_2_1_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/327524a0"},{"key":"e_1_2_1_144_1","unstructured":"\u2022\u2022Provided documentation of an earliersuggestion by Furchgott that endothelium derived relaxing factor is nitric oxide."},{"key":"e_1_2_1_145_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.11.4651"},{"key":"e_1_2_1_146_1","unstructured":"\u2022An important observation that nitric oxide modulates leukocyte function suggesting a broader role for nitric oxide in the cardiovascular system."},{"key":"e_1_2_1_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90510-Y"},{"key":"e_1_2_1_148_1","unstructured":"SCOTT-BURDEN T VANHOUTTE PM: The endothelium as a regulator of vascular smooth muscle proliferation. Circulation (1993) 87(Suppl. V):V51\u2013V55."},{"key":"e_1_2_1_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(91)90022-M"},{"key":"e_1_2_1_150_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292706"},{"key":"e_1_2_1_151_1","doi-asserted-by":"crossref","unstructured":"MAGGI M FILIPPI S LEDDA F MAGINI A FORTI G: Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur. 1 Eridocnnol. (2000) 143(2):143\u2013154.","DOI":"10.1530\/eje.0.1430143"},{"key":"e_1_2_1_152_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide - physiology, pathophysiology, and pharmacology","volume":"43","author":"MONCADA S PALMER RMJ","year":"1991","unstructured":"MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide - physiology, pathophysiology, and pharmacology. Pharmacol. Rev (1991) 43:109\u2013142.","journal-title":"Pharmacol. Rev"},{"key":"e_1_2_1_153_1","unstructured":"\u2022An excellent early review of the role of nitric oxide in the cardiovascular system."},{"key":"e_1_2_1_154_1","doi-asserted-by":"publisher","DOI":"10.1039\/cs9932200233"},{"key":"e_1_2_1_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(92)90008-W"},{"key":"e_1_2_1_156_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.12.1381691"},{"key":"e_1_2_1_157_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1281928"},{"key":"e_1_2_1_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/377239a0"},{"key":"e_1_2_1_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0146-0005(00)80064-6"},{"key":"e_1_2_1_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90615-W"},{"key":"e_1_2_1_161_1","doi-asserted-by":"crossref","unstructured":"KOBZIK L BREDT DS LOWENSTEIN CJ et al.: Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am. 1 Respit: Cell Ma. Biol. (1993) 9(4):371\u2013377.","DOI":"10.1165\/ajrcmb\/9.4.371"},{"key":"e_1_2_1_162_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2000.80.4.1337"},{"key":"e_1_2_1_163_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199907000-00003"},{"key":"e_1_2_1_164_1","doi-asserted-by":"crossref","unstructured":"STEUDEL W SCHERRER-CROSBIE M BLOCH KD et al.: Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3.j Clin. Invest. (1998) 101(10:2468\u20132477.","DOI":"10.1172\/JCI2356"},{"key":"e_1_2_1_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)61098-4"},{"key":"e_1_2_1_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90319-0"},{"key":"e_1_2_1_167_1","first-page":"H291\u2013H297","article-title":"Interactions of nitroglycerin and sulfhydryl-donating compounds in coronary microvessels","volume":"266","author":"WHEATLEY RM","year":"1994","unstructured":"WHEATLEY RM, DOCKERY SP, KURZ MA, SAYEGH HS, HARRISON DG: Interactions of nitroglycerin and sulfhydryl-donating compounds in coronary microvessels. Am. 1 Physiol. (1994) 266:H291\u2013H297.","journal-title":"Am. 1 Physiol."},{"key":"e_1_2_1_168_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3565(25)32738-2","article-title":"Mechanism of vascular smooth muscle relaxation by organic nitrates: evidence for the involvement of S-nitrosothiols as active intermediates","volume":"218","author":"IGNARRO LJ","year":"1981","unstructured":"IGNARRO LJ, LIPTON H, EDWARDS JC et al.: Mechanism of vascular smooth muscle relaxation by organic nitrates: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. (1981) 218:739\u2013749.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_169_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1995.tb00308.x"},{"key":"e_1_2_1_170_1","doi-asserted-by":"crossref","unstructured":"KOWALUK EA FUNG H-L: Vascular nitric oxide-generating activities for organic nitrites and organic nitrates are distinct. 1 Pharmacol. Exp. Ther. (1991) 259:519\u2013525.","DOI":"10.1016\/S0022-3565(25)20352-4"},{"key":"e_1_2_1_171_1","doi-asserted-by":"publisher","DOI":"10.1177\/026765910001500203"},{"key":"e_1_2_1_172_1","first-page":"S157\u2013S165","article-title":"Nitric oxide generation from nitroprusside by vascular tissue","volume":"42","author":"BATES JN","year":"1991","unstructured":"BATES JN, BAKER MT, GUERRA R, HARRISON DG: Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem. Pharmacol. (1991) 42:S157\u2013S165.","journal-title":"Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem. Pharmacol."},{"key":"e_1_2_1_173_1","doi-asserted-by":"crossref","unstructured":"NOACK E FEELISCH M: Molecular mechanisms of nitrovasodilator bioactivation. Basic Res. Cordial. (1991) 86\\(Suppl. 2):37\u201350.","DOI":"10.1007\/978-3-642-72461-9_5"},{"key":"e_1_2_1_174_1","first-page":"507","article-title":"A: S-Nitrosothiols: a class of nitric oxide-donor drugs","volume":"98","author":"AL-SADONI H","year":"2000","unstructured":"AL-SADONI H, FERRO A: S-Nitrosothiols: a class of nitric oxide-donor drugs. Gun. Sci. (2000) 98:507\u2013520.","journal-title":"Gun. Sci."},{"key":"e_1_2_1_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(99)00023-7"},{"key":"e_1_2_1_176_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04545.x"},{"key":"e_1_2_1_177_1","doi-asserted-by":"crossref","unstructured":"MORLEY D KEEFER LK: Nitric oxide\/ nucleophile complexes: a unique class of nitric oxide-based vasodilators. Cardiovasc. Pharmacy]. (1993) 22\\(Suppl. 7):S3\u2013S9.","DOI":"10.1097\/00005344-199300221-00003"},{"key":"e_1_2_1_178_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199401000-00016"},{"key":"e_1_2_1_179_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199808000-00026"},{"key":"e_1_2_1_180_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1998.84.2.435"},{"key":"e_1_2_1_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(99)90158-0"},{"key":"e_1_2_1_182_1","doi-asserted-by":"crossref","unstructured":"HOMER K WANSTALL J: In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries. Eur. PharinacoL (1998) 356(1):49\u201357 Websites","DOI":"10.1016\/S0014-2999(98)00511-1"},{"key":"e_1_2_2_2_1","unstructured":"http:\/\/www.who.int\/ncd\/cvd\/pph. html"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.10.7.1291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:52:53Z","timestamp":1770933173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.10.7.1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":179,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1517\/13543784.10.7.1291"],"URL":"https:\/\/doi.org\/10.1517\/13543784.10.7.1291","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}